<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03469284</url>
  </required_header>
  <id_info>
    <org_study_id>2016-1051</org_study_id>
    <secondary_id>NCI-2018-00822</secondary_id>
    <secondary_id>2016-1051</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT03469284</nct_id>
  </id_info>
  <brief_title>MOM's PAIN (Methylene Blue for Oral Mucositis' PAIN)</brief_title>
  <official_title>Randomized Controlled Trial Comparing 4 Intervention Arms, Including 3 Different Concentrations of Methylene Blue Oral Rinse Combined With Conventional Therapy and Conventional Therapy, in Patients With Intractable Pain Associated With Oral Mucositis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well methylene blue works in treating patients with cancer
      and pain associated with oral mucositis. Methylene blue may relieve pain associated with oral
      mucositis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To evaluate the efficacy of methylene blue (MB) in reducing the severity of
      mucositis-related pain, measured by numeric rating scale (NRS), in cancer patients who
      underwent or are undergoing chemotherapy or radiation therapy.

      OUTLINE: Patients are randomized to 1 of 4 groups.

      GROUP 1: Patients receive lower dose methylene blue orally (PO) to swish and spit for 5
      minutes every 6 hours then receive standard of care therapy.

      GROUP 2: Patients receive medium dose methylene blue PO to swish and spit for 5 minutes every
      6 hours then receive standard of care therapy.

      GROUP 3: Patients receive higher dose methylene blue PO to swish and spit for 5 minutes every
      6 hours then receive standard of care therapy.

      GROUP 4: Patients receive standard of care therapy.

      After completion of study treatment, patients are followed up at 1, 2, 7, and 30 days.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2019</start_date>
  <completion_date type="Anticipated">February 25, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 25, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in pain scores assessed within the Numeric Rating Scale (NRS) component of the Modified Harris mucositis-related pain assessment tool</measure>
    <time_frame>Baseline up to day 7</time_frame>
    <description>The mean change in scores will be compared among 4 arms, utilizing analysis of variance (ANOVA). If there are significant differences between intervention arms in some covariates, a linear regression model will be utilized to compare arms by adjusting for those significant covariates. The mean pain scores over time will be compared among study arms, utilizing linear mixed effects models. Covariates that showed significant differences among study arms will be adjusted in the linear mixed effects models. Two separate analyses, intention to treat and per protocol, will be conducted for primary analysis. Tukey's pairwise comparison will be conducted if a significant difference is observed among 4 arms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in the Modified Harris mucositis-related pain assessment tool scores</measure>
    <time_frame>Baseline up to day 7</time_frame>
    <description>Will be compared between study arms, utilizing ANOVA or Kruskal-Wallis test (eat, swallow, talk: unable=2, difficulty=1, able=0).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in oral functioning scores</measure>
    <time_frame>Baseline up to day 7</time_frame>
    <description>Will be compared between study arms, utilizing ANOVA or Kruskal-Wallis test (eat, swallow, talk: unable=2, difficulty=1, able=0. Oral functioning score is the total score of 3 categories, ranged 0-6).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of pain</measure>
    <time_frame>Up to day 7</time_frame>
    <description>Will determine difference between arms. Will utilize ANOVA, Kruskal-Wallist, Chi-square test, or Fisher's exact test as appropriate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scores</measure>
    <time_frame>Up to day 7</time_frame>
    <description>Will determine difference between arms. Will utilize ANOVA, Kruskal-Wallist, Chi-square test, or Fisher's exact test as appropriate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall analgesic use (including opiate use primarily used for oral mucositis pain via morphine-equivalent daily dose [MEDD] measurement)</measure>
    <time_frame>Up to day 7</time_frame>
    <description>Will determine difference between arms. Will utilize ANOVA, Kruskal-Wallist, Chi-square test, or Fisher's exact test as appropriate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of untoward side effects</measure>
    <time_frame>Up to day 7</time_frame>
    <description>Will determine difference between arms. Will utilize ANOVA, Kruskal-Wallist, Chi-square test, or Fisher's exact test as appropriate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance with methylene blue (MB) treatment</measure>
    <time_frame>Up to day 7</time_frame>
    <description>Will compare the dropout rate within the MB group to the dropout rate in the conventional therapy group utilizing Chi-square test or Fisher's exact test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of MB doses needed to achieve pain relief</measure>
    <time_frame>Up to day 2</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Malignant Neoplasm</condition>
  <condition>Oral Pain</condition>
  <condition>Stomatitis</condition>
  <arm_group>
    <arm_group_label>Group 1 (lower dose methylene blue, standard of care)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive lower dose methylene blue PO to swish and spit for 5 minutes every 6 hours then receive standard of care therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 (medium dose methylene blue, standard of care)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive medium dose methylene blue PO to swish and spit for 5 minutes every 6 hours then receive standard of care therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 (higher dose methylene blue, standard of care)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive higher dose methylene blue PO to swish and spit for 5 minutes every 6 hours then receive standard of care therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4 (standard of care)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive standard of care therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best Practice</intervention_name>
    <description>Given standard of care therapy</description>
    <arm_group_label>Group 1 (lower dose methylene blue, standard of care)</arm_group_label>
    <arm_group_label>Group 2 (medium dose methylene blue, standard of care)</arm_group_label>
    <arm_group_label>Group 3 (higher dose methylene blue, standard of care)</arm_group_label>
    <arm_group_label>Group 4 (standard of care)</arm_group_label>
    <other_name>standard of care</other_name>
    <other_name>standard therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylene Blue</intervention_name>
    <description>Given lower dose PO</description>
    <arm_group_label>Group 1 (lower dose methylene blue, standard of care)</arm_group_label>
    <other_name>Azul de Metileno</other_name>
    <other_name>Azul Metile</other_name>
    <other_name>Blu di Metilene</other_name>
    <other_name>CI Basic Blue 9</other_name>
    <other_name>CI-52015</other_name>
    <other_name>Collubleu</other_name>
    <other_name>Colour Index No. 52015</other_name>
    <other_name>Desmoidpillen</other_name>
    <other_name>Methylenum Caeruleum</other_name>
    <other_name>Methylthioninii Chloridum</other_name>
    <other_name>Methylthioninium Chloride</other_name>
    <other_name>Schultz No. 1038</other_name>
    <other_name>Tetramethylthionine Chloride Trihydrate</other_name>
    <other_name>Urolene Blue</other_name>
    <other_name>Vitableu</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylene Blue</intervention_name>
    <description>Given medium dose PO</description>
    <arm_group_label>Group 2 (medium dose methylene blue, standard of care)</arm_group_label>
    <other_name>Azul de Metileno</other_name>
    <other_name>Azul Metile</other_name>
    <other_name>Blu di Metilene</other_name>
    <other_name>CI Basic Blue 9</other_name>
    <other_name>CI-52015</other_name>
    <other_name>Collubleu</other_name>
    <other_name>Colour Index No. 52015</other_name>
    <other_name>Desmoidpillen</other_name>
    <other_name>Methylenum Caeruleum</other_name>
    <other_name>Methylthioninii Chloridum</other_name>
    <other_name>Methylthioninium Chloride</other_name>
    <other_name>Schultz No. 1038</other_name>
    <other_name>Tetramethylthionine Chloride Trihydrate</other_name>
    <other_name>Urolene Blue</other_name>
    <other_name>Vitableu</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylene Blue</intervention_name>
    <description>Given higher dose PO</description>
    <arm_group_label>Group 3 (higher dose methylene blue, standard of care)</arm_group_label>
    <other_name>Azul de Metileno</other_name>
    <other_name>Azul Metile</other_name>
    <other_name>Blu di Metilene</other_name>
    <other_name>CI Basic Blue 9</other_name>
    <other_name>CI-52015</other_name>
    <other_name>Collubleu</other_name>
    <other_name>Colour Index No. 52015</other_name>
    <other_name>Desmoidpillen</other_name>
    <other_name>Methylenum Caeruleum</other_name>
    <other_name>Methylthioninii Chloridum</other_name>
    <other_name>Methylthioninium Chloride</other_name>
    <other_name>Schultz No. 1038</other_name>
    <other_name>Tetramethylthionine Chloride Trihydrate</other_name>
    <other_name>Urolene Blue</other_name>
    <other_name>Vitableu</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a cancer diagnosis, receiving chemotherapy, radiation therapy or the
             combination

          -  Patients with a current diagnosis of oral mucositis

          -  Patients with pain and oral dysfunction associated with oral mucositis despite
             conventional therapy

          -  Voluntary written consent

          -  Patient must agree to use of contraception or abstinence from sex during the treatment
             period and for 30 days after patient's last dose

        Exclusion Criteria:

          -  Patients with known allergy to MB

          -  Patients taking medications with known significant drug interactions

          -  Pregnant or lactating patients

          -  Patients who are cognitively impaired and unable to consent for the study

          -  Patients with risk of broncho-aspiration based on documented swallowing test by a
             speech pathologist (if available)

          -  Patients with known history of G6PD deficiency

          -  Patients undergoing any other experimental intervention for oral mucositis

          -  Patients who have no pain or impairment in oral function, patients who are not
             symptomatic

          -  Patients with head and neck cancer

          -  Patients on serotonergic drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Roldan</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carlos Roldan</last_name>
    <phone>713-792-6070</phone>
    <email>croldan@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Roldan</last_name>
      <phone>713-792-6070</phone>
    </contact>
    <investigator>
      <last_name>Carlos Roldan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 13, 2018</study_first_submitted>
  <study_first_submitted_qc>March 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2018</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucositis</mesh_term>
    <mesh_term>Stomatitis</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylene Blue</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

